trending Market Intelligence /marketintelligence/en/news-insights/trending/yc7vjlai5bjwbunl-o2oaq2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Protalix BioTherapeutics appoints independent director


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Protalix BioTherapeutics appoints independent director

Protalix BioTherapeutics Inc. appointed David Granot to its board as an independent director.

Granot brings his financial and banking knowledge to the company. He was the CEO of First International Bank of Israel Ltd. from 2001 to 2007. He also served as the CEO of the Israel Discount Bank Ltd. from 1998 to 2000.

Israel-based Protalix BioTherapeutics is a biotechnology company engaged in the development and commercialization of recombinant therapeutic proteins using ProCellEx, its proprietary plant cell-based expression system.